Cambrex Corp has signed a letter of intent to buy Celgene's chiralintermediate business for up to $15 million. Part of the transaction will be the rights to Celgene's enzymatic technology for the production of chirally-pure products for the pharmaceutical industry, including the current pipeline of third-party products under development and the equipment and personnel associated with the business. Terms of the deal provide for $7.5 million being paid on closing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze